
    
      To investigate whether sequential combination therapy with Thymosin alpha 1 and entecavir is
      superior to continuous ETV monotherapy in HBeAg-positive chronic hepatitis B patients with
      previous long-term entecavir therapy (â‰¥ 1 years), and to select the optimal patients who may
      benefit from sequential combination therapy.
    
  